Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biotech InnovationGene therapy holds transformative potential for treating complex diseases, but safety concerns remain paramount. Capsida's recent silence regarding the specific brain receptor targeted in its halted trial has frustrated the field and underscores the need for transparency in investigating adverse outcomes linked to novel therapies.
Emily CarterMay 12, 2026
AI in Drug DiscoveryAs artificial intelligence continues to advance within healthcare, physical therapists explore how to incorporate AI effectively and ethically into musculoskeletal (MSK) care. Establishing trust in these technologies and implementing clear operational rules are critical for successful integration.
Emily CarterMay 6, 2026
Healthcare InvestmentAs the biopharmaceutical sector navigates a changing public market landscape, companies like Odyssey and Seaport Therapeutics are at the forefront of a renewed IPO momentum. Analysts remain cautiously optimistic about the implications of these moves for industry investors.
Emily CarterMay 4, 2026
Regulatory & PolicyThe recent FDA expansion of Auvelity’s label to include agitation in Alzheimer's disease marks a significant milestone in managing this challenging symptom. As only the second FDA-approved option, Auvelity offers a novel, non-antipsychotic approach with safety advantages, bringing hope to patients and caregivers alike.
Emily CarterMay 4, 2026
Regulatory & PolicyAuvelity by Axsome marks a breakthrough in the treatment of agitation in Alzheimer's patients, offering a novel therapeutic alternative distinct from antipsychotics. Analysts predict this approval could translate into a substantial commercial success, reflecting unmet needs in neuropsychiatric symptom management in Alzheimer's disease.
Emily CarterMay 1, 2026
Biopharmaceutical IndustryThe healthcare sector in April 2026 experienced a whirlwind of personnel changes that reflect broader trends in the industry’s adaptation to evolving market demands and operational challenges. This post unpacks the key developments across leading companies and organizations.
Emily CarterMay 1, 2026
Regulatory & PolicyThe frequency and severity of wildfires have escalated globally, leading to increased emissions of harmful pollutants. New data reveal not only more frequent exposure to wildfire smog but also an increase in its toxicity, which has significant implications for respiratory and cardiovascular health.
Emily CarterApr 30, 2026
Drug DevelopmentThe recent crash in Compass Biotechnology’s stock price reflects market concerns about the approvability of its bispecific antibody, following the emergence of perplexing survival data. Industry analysts and investors are evaluating the implications for future drug development strategies.
Emily CarterApr 28, 2026
Regulatory & PolicyAfter decades dominated by the "Just Say No" approach, GOP drug policy is undergoing profound changes. These include federal funding for psychedelics research and reclassification efforts for state-licensed medical marijuana, reflecting evolving attitudes toward drug reform within the party. This shift may have broad implications for healthcare, policy, and societal perspectives on treatment options.
Emily CarterApr 23, 2026
Biotech InnovationAdvancements in cardiovascular risk management are underway as BioAge announces promising early results for its investigational pill that significantly mitigates inflammation, a key underlying factor in cardiovascular disease development. These findings underscore a potential new approach to reducing heart risks through modulation of inflammatory processes.
Emily CarterApr 21, 2026
Biotech InnovationThe American Association of Cancer Researchers' 2026 meeting showcased pioneering research in CAR-T immunotherapy. This includes bold approaches to targeting smoldering multiple myeloma, with trial data offering new hope for high-risk patients by potentially preventing the onset of active disease. The session also touched upon Merck’s strategic oncology initiatives and highlighted rural health disparities.
Emily CarterApr 21, 2026
Biopharmaceutical IndustryPharmaceutical companies are entering the first quarter earnings reports season with anticipation focused on innovative drugs and strategic deals. Novo Nordisk will lead with revealing revenue numbers from its oral GLP-1 medication, setting the pace for discussions around approvals, pricing, and external economic pressures including new tariffs.
Emily CarterApr 14, 2026